$1.41
1.44% today
Nasdaq, Sep 30, 06:37 pm CET
ISIN
IL0011313900
Symbol
GLMD

Galmed Pharmaceuticals Ltd. Stock price

$1.39
+0.12 9.45% 1M
-0.05 3.47% 6M
-1.80 56.43% YTD
-5.47 79.74% 1Y
-55.20 97.54% 3Y
-621.41 99.78% 5Y
-1,332.41 99.90% 10Y
-2,574.41 99.95% 20Y
Nasdaq, Closing price Mon, Sep 29 2025
-0.01 0.71%
ISIN
IL0011313900
Symbol
GLMD
Industry

Key metrics

Basic
Market capitalization
$7.6m
Enterprise Value
$-12.9m
Net debt
positive
Cash
$20.5m
Shares outstanding
5.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
2.4
P/B
0.4
Financial Health
Equity Ratio
88.3%
Return on Equity
-46.1%
ROCE
-34.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-7.0m | -
EBIT
$-7.0m | $-5.8m
Net Income
$-8.7m | $-17.6m
Free Cash Flow
$-5.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-14.3% | -
EBIT
-12.6% | 7.9%
Net Income
-48.0% | -134.3%
Free Cash Flow
7.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.2
FCF per Share
$-1.0
Short interest
1.8%
Employees
5
Rev per Employee
$0.0
Show more

Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Galmed Pharmaceuticals Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

Hold
50%
Sell
50%

Financial data from Galmed Pharmaceuticals Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.53 3.53
4% 4%
-
- Research and Development Expense 3.50 3.50
23% 23%
-
-7.03 -7.03
14% 14%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -7.03 -7.03
13% 13%
-
Net Profit -8.72 -8.72
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galmed Pharmaceuticals Ltd. Stock News

Neutral
PRNewsWire
about one month ago
TEL AVIV, Israel , Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three and six months ended June 30, 2025 and recent developments.
Neutral
PRNewsWire
about one month ago
An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company's Special General Meeting of shareholders held on August 15, 2025 The Company is initially planning to invest up to $10M representing approximately 50% of its current cash balance to be deployed in execution of ...
Neutral
PRNewsWire
4 months ago
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.
More Galmed Pharmaceuticals Ltd. News

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Allen Baharaff
Employees 5
Founded 2000
Website www.galmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today